Source comparison
MK-677 Bone Density Results Timeline Expect: Protocol Comparison
| Protocol | Dose | Duration | Lumbar BMD Change | Femoral Neck BMD Change | Key Population | Professional Assessment ||—|—|—|—|—|—|| JCEM 2021 Trial | 25mg daily | 18 months | +4.2% vs +0.8% placebo | +2.1% vs +0.3% placebo | Adults 65+ with low IGF-1 | Stati
This comparison does not assign a generated winner or score.
- | Protocol | Dose | Duration | Lumbar BMD Change | Femoral Neck BMD Change | Key Population | Professional Assessment ||—|—|—|—|—|—|| JCEM 2021 Trial | 25mg daily | 18 months | +4.2% vs +0.8% placebo | +2.1% vs +0.3% placebo | Adults 65+ with low IGF-1 | Statistically significant but slow. No change before month 12. Requires patience and compliance. || Short-Cycle Protocol | 20mg daily | 6 months | +0.5% (not significant) | +0.2% (not significant) | Mixed-age research subjects | Too short to produce meaningful skeletal adaptation. Bone turnover markers improved but DEXA unchanged. || Extended Protocol | 15mg daily | 24 months | +5.8% vs baseline | +3.4% vs baseline | Postmenopausal women with osteopenia | Peak results at 24 months. Gains plateaued between months 18–24, suggesting saturation point. || High-Dose Protocol | 50mg daily | 12 months | +3.1% vs baseline | +1.8% vs baseline | Elderly men with sarcopenia | Higher side effect burden (edema, fasting glucose elevation) without pro